Psilocybin, the psychoactive ingredient in “magic mushrooms,” is attracting increasing interest from scientists studying treatments for neuropsychiatric conditions such as depression, anxiety, substance use disorders, and certain neurodegenerative diseases. While research suggests the compound may have therapeutic value, its strong hallucinogenic effects could limit how widely it is used in medicine.

In a study published in ACS’ Journal of Medicinal Chemistry, researchers developed modified forms of psilocin, the active compound produced from psilocybin in the body. In early experiments with mice, these altered molecules maintained biological activity but triggered fewer hallucinogenic-like effects than pharmaceutical-grade psilocybin.

“Our findings are consistent with a growing scientific perspective suggesting that psychedelic effects and serotonergic activity may be dissociated,” says Andrea Mattarei, a corresponding author of the study. “This opens the possibility of designing new therapeutics that retain beneficial biological activity while reducing hallucinogenic responses, potentially enabling safer and more practical treatment strategies.”